FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000622572> ?p ?o ?g. }

• W2000622572 endingPage "526" @default.
• W2000622572 startingPage "526" @default.
• W2000622572 abstract "<h3>Purpose</h3> Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no prospective studies have been published. We report results for angiosarcoma treated with ipilimumab and nivolumab as a cohort of an ongoing rare cancer study. <h3>Methods</h3> This is a prospective, open-label, multicenter phase II clinical trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks) for metastatic or unresectable angiosarcoma. Primary endpoint was objective response rate (ORR) per RECIST 1.1. Secondary endpoints include progression-free (PFS) and overall survival, and toxicity. A two-stage design was used. <h3>Results</h3> Overall, there were 16 evaluable patients. Median age was 68 years (range, 25–81); median number of prior lines of therapy, 2. Nine patients had cutaneous and seven non-cutaneous primary tumors. ORR was 25% (4/16). Sixty per cent of patients (3/5) with primary cutaneous scalp or face tumors attained a confirmed response. Six-month PFS was 38%. Altogether, 75% of patients experienced an adverse event (AE) (at least possibly related to drug) (25% grade 3–4 AE); 68.8%, an immune-related AE (irAE) (2 (12.5%), grade 3 or 4 irAEs (alanine aminotransferase/aspartate aminotransferase increase and diarrhea)). There were no grade 5 toxicities. One of seven patients in whom tumor mutation burden (TMB) was assessed showed a high TMB (24 mutations/mb); that patient achieved a partial response (PR). Two of three patients with PDL1 immunohistochemistry assessed had high PDL1 expression; one achieved a PR. <h3>Conclusion</h3> The combination of ipilimumab and nivolumab demonstrated an ORR of 25% in angiosarcoma, with three of five patients with cutaneous tumors of the scalp or face responding. Ipilimumab and nivolumab warrant further investigation in angiosarcoma. <h3>Trial registration number</h3> NCT02834013." @default.
• W2000622572 created "2016-06-24" @default.
• W2000622572 creator A5056945166 @default.
• W2000622572 creator A5078514267 @default.
• W2000622572 date "1976-02-28" @default.
• W2000622572 modified "2023-09-24" @default.
• W2000622572 title "Fair allocation of resources" @default.
• W2000622572 doi "https://doi.org/10.1136/bmj.1.6008.526-c" @default.
• W2000622572 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1638852" @default.
• W2000622572 hasPublicationYear "1976" @default.
• W2000622572 type Work @default.
• W2000622572 sameAs 2000622572 @default.
• W2000622572 citedByCount "1" @default.
• W2000622572 countsByYear W20006225722015 @default.
• W2000622572 crossrefType "journal-article" @default.
• W2000622572 hasAuthorship W2000622572A5056945166 @default.
• W2000622572 hasAuthorship W2000622572A5078514267 @default.
• W2000622572 hasBestOaLocation W20006225722 @default.
• W2000622572 hasConcept C136764020 @default.
• W2000622572 hasConcept C2522767166 @default.
• W2000622572 hasConcept C29202148 @default.
• W2000622572 hasConcept C31258907 @default.
• W2000622572 hasConcept C41008148 @default.
• W2000622572 hasConceptScore W2000622572C136764020 @default.
• W2000622572 hasConceptScore W2000622572C2522767166 @default.
• W2000622572 hasConceptScore W2000622572C29202148 @default.
• W2000622572 hasConceptScore W2000622572C31258907 @default.
• W2000622572 hasConceptScore W2000622572C41008148 @default.
• W2000622572 hasIssue "6008" @default.
• W2000622572 hasLocation W20006225721 @default.
• W2000622572 hasLocation W20006225722 @default.
• W2000622572 hasOpenAccess W2000622572 @default.
• W2000622572 hasPrimaryLocation W20006225721 @default.
• W2000622572 hasRelatedWork W2111447838 @default.
• W2000622572 hasRelatedWork W2323581027 @default.
• W2000622572 hasRelatedWork W2382084165 @default.
• W2000622572 hasRelatedWork W2748952813 @default.
• W2000622572 hasRelatedWork W2799555207 @default.
• W2000622572 hasRelatedWork W2995391442 @default.
• W2000622572 hasRelatedWork W3128488559 @default.
• W2000622572 hasRelatedWork W4229025465 @default.
• W2000622572 hasRelatedWork W4283067488 @default.
• W2000622572 hasRelatedWork W4311257609 @default.
• W2000622572 hasVolume "1" @default.
• W2000622572 isParatext "false" @default.
• W2000622572 isRetracted "false" @default.
• W2000622572 magId "2000622572" @default.
• W2000622572 workType "article" @default.